Market Exclusive

Analyst Activity – Barclays Raises Its Price Target On Myriad Genetics (NASDAQ:MYGN) to $35.00

Analyst Ratings For Myriad Genetics (NASDAQ:MYGN)

Today, Barclays raised its price target on Myriad Genetics (NASDAQ:MYGN) to $35.00 per share.

Some recent analyst ratings include


Recent Trading Activity for Myriad Genetics (NASDAQ:MYGN)
Shares of Myriad Genetics closed the previous trading session at 39.85 up +1.23 3.18% with 38.47999954223633 shares trading hands.

Exit mobile version